skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

11983

Profile of ipilimumab and its role in the treatment of metastatic melanoma



Review

(6095) Total Article Views


Authors: Patel SP, Woodman SE

Published Date December 2011 Volume 2011:5 Pages 489 - 495
DOI: http://dx.doi.org/10.2147/DDDT.S10945

Sapna P Patel, Scott E Woodman
Melanoma Medical Oncology Department, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Abstract: Melanoma is an immunogenic cancer. However, the ability of the immune system to eradicate melanoma tumors is affected by intrinsic negative regulatory mechanisms. Multiple immune-modulatory therapies are currently being developed to optimize the immune response to melanoma tumors. Two recent Phase III studies using the monoclonal antibody ipilimumab, which targets the cytotoxic T-lymphocyte antigen (CTLA-4), a negative regulator of T-cell activation, have demonstrated improvement in overall survival of metastatic melanoma patients. This review highlights the clinical trial data that supports the efficacy of ipilimumab, the immune-related response criteria used to evaluate clinical response, and side-effect profile associated with ipilimumab treatment.

Keywords: ipilimumab, melanoma, T-cells, CTLA-4



Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read:
  • Testimonials

    "I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.